Large Cell Lung Carcinoma
Associated Genetic Biomarkers
NCI Definition: A poorly differentiated non-small cell lung carcinoma composed of large polygonal cells without evidence of glandular or squamous differentiation. There is a male predilection. 
Large cell lung carcinomas most frequently harbor alterations in TP53, KRAS, STK11, KEAP1, and CDKN2A .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in large cell lung carcinoma .
There are 2 clinical trials for large cell lung carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain large cell lung carcinoma as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
PD-L1 is the most frequent gene inclusion criterion for large cell lung carcinoma clinical trials .
Imu-201, nivolumab, and standard of care are the most common interventions in large cell lung carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.